Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Nahon

Showing results (131-140 of 205) with videos related to

Pageof 21
Sort By:
Hepatology (Baltimore, Md.)|October 23, 2023
Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumabClaudia Campani, Ariane Vallot, Haroun Ghannouchi, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 20, 2013
Serum proteoglycans as prognostic biomarkers of hepatocellular carcinoma in patients with alcoholic cirrhosisJean-Charles Nault, Erwan Guyot, Christelle Laguillier, et al.
Scientific Reports|November 5, 2022
Imaging and histological features of tumor biopsy sample predict aggressive intrasegmental recurrence of hepatocellular carcinoma after radiofrequency ablationElia Gigante, Yohann Haddad, Jean-Charles Nault, et al.
JHEP Reports : Innovation in Hepatology|April 8, 2026
Comparative evaluation of regression and machine-learning models for hepatocellular carcinoma risk stratification across diverse aetiologiesPierre Nahon, Richard Layese, Pierre-André Natella, et al.
Journal of Hepatology|August 30, 2023
Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumabWendy Limousin, Pierre Laurent-Puig, Marianne Ziol, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 11, 2021
Percutaneous radiofrequency ablation for hepatocellular carcinoma developed on non-alcoholic fatty liver diseaseNga Nguyen, Agnès Rode, Hervé Trillaud, et al.
Journal of Hepatology|December 13, 2023
Preventing liver disease with policy measures to tackle alcohol consumption and obesity: The HEPAHEALTH II studyLise Retat, Laura Webber, Peter Jepsen, et al.
BMC Medicine|November 12, 2020
Serum keratin 19 (CYFRA21-1) links ductular reaction with portal hypertension and outcome of various advanced liver diseasesKarim Hamesch, Nurdan Guldiken, Mahmoud Aly, et al.
Cancers|June 10, 2022
Impact of Extended Use of Ablation Techniques in Cirrhotic Patients with Hepatocellular Carcinoma: A Cost-Effectiveness AnalysisToulsie Ramtohul, Valérie Vilgrain, Olivier Soubrane, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 4, 2024
Long-term oncological results of percutaneous radiofrequency ablation for intrahepatic cholangiocarcinomaClémentine Alitti, Agnès Rode, Hervé Trillaud, et al.
Pageof 21

Showing results (131-140 of 205) with videos related to

Sort By:
Pageof 21
Hepatology (Baltimore, Md.)|October 23, 2023
Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumabClaudia Campani, Ariane Vallot, Haroun Ghannouchi, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 20, 2013
Serum proteoglycans as prognostic biomarkers of hepatocellular carcinoma in patients with alcoholic cirrhosisJean-Charles Nault, Erwan Guyot, Christelle Laguillier, et al.
Scientific Reports|November 5, 2022
Imaging and histological features of tumor biopsy sample predict aggressive intrasegmental recurrence of hepatocellular carcinoma after radiofrequency ablationElia Gigante, Yohann Haddad, Jean-Charles Nault, et al.
JHEP Reports : Innovation in Hepatology|April 8, 2026
Comparative evaluation of regression and machine-learning models for hepatocellular carcinoma risk stratification across diverse aetiologiesPierre Nahon, Richard Layese, Pierre-André Natella, et al.
Journal of Hepatology|August 30, 2023
Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumabWendy Limousin, Pierre Laurent-Puig, Marianne Ziol, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 11, 2021
Percutaneous radiofrequency ablation for hepatocellular carcinoma developed on non-alcoholic fatty liver diseaseNga Nguyen, Agnès Rode, Hervé Trillaud, et al.
Journal of Hepatology|December 13, 2023
Preventing liver disease with policy measures to tackle alcohol consumption and obesity: The HEPAHEALTH II studyLise Retat, Laura Webber, Peter Jepsen, et al.
BMC Medicine|November 12, 2020
Serum keratin 19 (CYFRA21-1) links ductular reaction with portal hypertension and outcome of various advanced liver diseasesKarim Hamesch, Nurdan Guldiken, Mahmoud Aly, et al.
Cancers|June 10, 2022
Impact of Extended Use of Ablation Techniques in Cirrhotic Patients with Hepatocellular Carcinoma: A Cost-Effectiveness AnalysisToulsie Ramtohul, Valérie Vilgrain, Olivier Soubrane, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 4, 2024
Long-term oncological results of percutaneous radiofrequency ablation for intrahepatic cholangiocarcinomaClémentine Alitti, Agnès Rode, Hervé Trillaud, et al.
Pageof 21